Today: 27 April 2026
Browse Category

Stock Market 10 February 2026

Reddit (RDDT) stock jumps 5% in afternoon trade as Wall Street resets targets

Reddit (RDDT) stock jumps 5% in afternoon trade as Wall Street resets targets

Reddit shares jumped 5.4% to $149.38 Tuesday, swinging as high as $152.34 while major indexes were flat or down. Analysts adjusted price targets after last week’s strong earnings and a $1 billion buyback plan. Fourth-quarter revenue rose 70% to $726 million, with daily active users up 19%. Investors are watching for buyback timing and the next earnings report, expected April 30.
10 February 2026
··
CrowdStrike (CRWD) stock rises as JPMorgan flags ‘AI-disruption’ selloff as overdone

CrowdStrike (CRWD) stock rises as JPMorgan flags ‘AI-disruption’ selloff as overdone

CrowdStrike shares rose 2.2% to $417.09 in afternoon trading Tuesday, leading gains in cybersecurity stocks. The move follows a steep slide in software valuations tied to AI disruption fears, with strategists at JPMorgan and Morgan Stanley calling the drop sentiment-driven. Investors are watching for CrowdStrike’s fiscal Q4 results due March 3. Thirty-day implied volatility in tech software ETFs remains near 10-month highs.
10 February 2026
··
DoorDash stock slips as U.S. retail sales stall — earnings next week loom

DoorDash stock slips as U.S. retail sales stall — earnings next week loom

DoorDash shares slipped 0.3% to $185.73 in Tuesday afternoon trading ahead of its Feb. 18 earnings report. Investors are watching for signals on demand, spending, and margins amid flat U.S. retail sales and pending jobs and inflation data. New York courts recently rejected DoorDash’s bid to block city tipping laws, with appeals planned. The company’s earnings call is set for 5 p.m. ET after markets close.
10 February 2026
··
Aon stock price bounces after ChatGPT insurance app spooks brokers — what investors watch next

Aon stock price bounces after ChatGPT insurance app spooks brokers — what investors watch next

Aon shares rose 3.1% to $319.86 Tuesday afternoon, rebounding after a steep Monday drop triggered by the launch of Insurify’s ChatGPT-based insurance comparison tool. Investors remain focused on whether AI-driven apps could pressure broker fees. Aon also announced a $25 million Ukraine war-risk reinsurance facility backed by the U.S. International Development Finance Corporation. WTW and Gallagher shares saw mixed moves.
10 February 2026
····
Nebius (NBIS) stock rises after Tavily acquisition, with February 12 earnings next

Nebius (NBIS) stock rises after Tavily acquisition, with February 12 earnings next

Nebius Group shares rose about 1% after the company agreed to acquire AI search provider Tavily for an undisclosed sum, with cash upfront and a performance-based earn-out. The deal was announced two days before Nebius reports quarterly results. Tavily’s software will be integrated into Nebius’s Token Factory platform. Investors await Thursday’s earnings for more details on demand and spending.
10 February 2026
···
IBM stock dips on ex-dividend day as it rolls out agentic AI FlashSystem storage

IBM stock dips on ex-dividend day as it rolls out agentic AI FlashSystem storage

IBM shares fell 1.4% to $292.19 Tuesday, underperforming a flat market after trading ex-dividend and launching new FlashSystem storage products built around “agentic AI.” The company said the new systems, available March 6, can cut manual storage work by up to 90% and detect ransomware in under a minute. IBM’s board approved a $1.68 per share dividend, payable March 10.
10 February 2026
··
Seagate (STX) stock price slides 6% as AI-storage names retreat; jobs and CPI next

Seagate (STX) stock price slides 6% as AI-storage names retreat; jobs and CPI next

Seagate Technology shares fell 6.1% to $399.15 by 2:17 p.m. ET Tuesday, deepening losses in AI-linked storage hardware as the broader market stayed steady. Western Digital dropped 7.2% and Intel lost 5.6%. The moves followed Amazon’s sharp decline last week and came amid delayed U.S. economic data, including flat December retail sales. No new company-specific news drove Seagate’s drop.
10 February 2026
··
Applied Digital stock price swings as SEC filing reveals big lease targets for top executives

Applied Digital stock price swings as SEC filing reveals big lease targets for top executives

Applied Digital shares were nearly flat at $38.18 Tuesday afternoon after wide swings, following an SEC filing detailing five-year equity awards tied to hyperscaler lease signings and data-center launches. The company granted performance-based stock units to top executives, vesting on long-term contracts and data center capacity targets. Bitcoin slipped 2% as crypto-linked infrastructure stocks also traded lower.
10 February 2026
·
Amphenol stock steadies near $145 after Monday bounce; what APH investors watch next

Amphenol stock steadies near $145 after Monday bounce; what APH investors watch next

Amphenol shares rose 0.2% to $144.44 in Tuesday afternoon trading, following a 5.9% jump Monday after earnings topped guidance. The board approved a $0.25 per share dividend, payable April 14 to holders as of March 23. Chairman Martin Loeffler will retire at the 2026 annual meeting, with CEO R. Adam Norwitt set to succeed him. Director Robert Livingston bought 10,000 shares at $128.51 on Feb. 5.
10 February 2026
·
AbbVie stock price rises as analysts reset targets and Wall Street waits on delayed jobs data

AbbVie stock price rises as analysts reset targets and Wall Street waits on delayed jobs data

AbbVie shares rose 0.7% to $224.83 Tuesday afternoon, near the session high, after BNP Paribas Exane raised its price target to $213 but kept a neutral rating. The stock traded in a narrow range as investors awaited delayed U.S. payrolls and inflation data for rate signals. U.S. stocks were mixed, with the Dow at a record high and S&P 500 little changed.
10 February 2026
··
1 … 154 155 156 157 158 … 1,393

Stock Market Today

  • SLV vs. SIVR: Comparing Silver ETFs for Long-Term Investors
    April 27, 2026, 3:49 PM EDT. The silver ETF market features two major players: iShares Silver Trust (SLV) and abrdn Physical Silver Shares ETF (SIVR). Both track physical silver, yet their expense ratios differ significantly. SLV charges 0.5% annually, while SIVR's effective fee is 0.3% due to a fee waiver, making SIVR more cost-effective for long-term investors. Silver prices have surged recently, fueled by increasing demand from renewable energy and data centers. Although SLV manages about $31 billion more in assets than SIVR, investors seeking lower costs may favor SIVR. Fee differences can substantially affect returns over time, making cost a crucial consideration when choosing between these two closely matched silver ETFs.

Latest article

Intellia Therapeutics CRISPR Trial Win Puts One-Time HAE Drug On FDA Track

Intellia Therapeutics CRISPR Trial Win Puts One-Time HAE Drug On FDA Track

27 April 2026
Intellia Therapeutics reported its CRISPR drug lonvo-z cut hereditary angioedema attacks by 87% versus placebo in a late-stage trial, with 62% of treated patients attack- and therapy-free over six months. The company has started a rolling U.S. approval application. No serious adverse events were reported. Intellia shares fell 0.9% to $13.51 after initial gains.
U.S. Energy Corp Stock Jumps as $285 Helium Deal Gives Big Sky a Buyer

U.S. Energy Corp Stock Jumps as $285 Helium Deal Gives Big Sky a Buyer

27 April 2026
U.S. Energy Corp. signed a five-year helium sales deal with an unnamed global industrial gas company, securing a buyer for output from its planned Big Sky Carbon Hub in Montana. The contract covers up to 1.2 million cubic feet a month at a fixed $285 per thousand cubic feet, with inflation adjustments starting March 2028. U.S. Energy shares rose 20.8% to $1.12 on heavy volume. The agreement is “take-or-pay,” with the buyer handling pickup at the plant.
Veradermics Stock Jumps After VDPHL01 Hair-Loss Pill Hits Trial Goals

Veradermics Stock Jumps After VDPHL01 Hair-Loss Pill Hits Trial Goals

27 April 2026
Veradermics shares rose 40% Monday after its oral hair-loss drug VDPHL01 met all main goals in a Phase 2/3 trial of 519 men. Patients taking the drug saw average hair count increases of 30.3 to 33.0 hairs per square centimeter over six months, compared to 7.3 for placebo. No treatment-related serious or heart-related adverse events were reported.
Go toTop